- Home
- JHI vs ATOS Comparison
JHI vs ATOS Comparison
Compare JHI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- ATOS
- Stock Information
- Founded
- JHI 1971
- ATOS 2009
- Country
- JHI United States
- ATOS United States
- Employees
- JHI N/A
- ATOS N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- ATOS Health Care
- Exchange
- JHI Nasdaq
- ATOS Nasdaq
- Market Cap
- JHI 125.7M
- ATOS 107.2M
- IPO Year
- JHI N/A
- ATOS 2012
- Fundamental
- Price
- JHI $14.22
- ATOS $0.83
- Analyst Decision
- JHI
- ATOS Strong Buy
- Analyst Count
- JHI 0
- ATOS 3
- Target Price
- JHI N/A
- ATOS $6.17
- AVG Volume (30 Days)
- JHI 29.5K
- ATOS 459.7K
- Earning Date
- JHI 01-01-0001
- ATOS 11-11-2025
- Dividend Yield
- JHI 6.80%
- ATOS N/A
- EPS Growth
- JHI N/A
- ATOS N/A
- EPS
- JHI 1.05
- ATOS N/A
- Revenue
- JHI N/A
- ATOS N/A
- Revenue This Year
- JHI N/A
- ATOS N/A
- Revenue Next Year
- JHI N/A
- ATOS N/A
- P/E Ratio
- JHI $12.47
- ATOS N/A
- Revenue Growth
- JHI N/A
- ATOS N/A
- 52 Week Low
- JHI $11.63
- ATOS $0.55
- 52 Week High
- JHI $13.40
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- JHI 51.62
- ATOS 57.66
- Support Level
- JHI $14.14
- ATOS $0.81
- Resistance Level
- JHI $14.46
- ATOS $0.85
- Average True Range (ATR)
- JHI 0.12
- ATOS 0.03
- MACD
- JHI -0.01
- ATOS 0.01
- Stochastic Oscillator
- JHI 30.95
- ATOS 80.10
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.